GB2153686A — Intravaginal device
Assigned to Dunlop Ltd · Expires 1985-08-29 · 41y expired
What this patent protects
An intravaginal contraceptive or therapeutic device comprises a resiliently compressible substantially cylindrical one-piece open-cellular polyurethane foam body (1) having a substantially centrally positioned surface depression (2) at its forward end and having a removal string …
USPTO Abstract
An intravaginal contraceptive or therapeutic device comprises a resiliently compressible substantially cylindrical one-piece open-cellular polyurethane foam body (1) having a substantially centrally positioned surface depression (2) at its forward end and having a removal string (3) attached at the base of the depression (4) and extending through the device body and out of the end of the body remote from the depression, the dimensions of the body being such that when the device is inside the vaginal cavity the device is retained therein by sealing engagement of the cylindrical surface with the cavity wall and the dimensions of the depression being such that the wall of the depression is able to close resiliently on lateral compression to form a taper for ease of insertion and location of the device in the vaginal cavity and to shield the string attachment means from contact with the cavity wall during and after insertion of the device. <IMAGE>
Drugs covered by this patent
- Azelex (AZELAIC ACID) · Leo Pharma As
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.